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B-Cell Depletion in Immune Thrombocytopenia
Bertrand GodeauB cells play an important role in the immune response and can lead to the development of0037-1963
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Seminarsautoimmune diseases and particularly immune thrombocytopenia (ITP). A rational approach to
ITP treatment could involve B-cell depletion such as with rituximab. Rituximab is a chimeric
monoclonal antibody directed against CD20 molecule. It has direct effects on antibody
production and indirect effects on cellular immunity. Rituximab demonstrated an overall
response rate of 62.5% that lasted from 2–48 months. The ability of rituximab as an effective
splenectomy-avoiding option was recently confirmed in a meta-analysis of randomized clinical
trials and observational studies including 368 patients with an overall response rate of 57%.
However, the estimated 5- year response is only 21% in adults. Rituximab appears to be well
tolerated, but we lack studies of long-term tolerance. The optimal time to administer rituximab
for ITP remains unclear. There is consensus to administer corticosteroids or intravenous
immunoglobulin (IVIg) as first-line therapy in ITP. A panel of experts was unable to formulate a
clear strategy for the respective place of splenectomy, thrombopoietin-receptor agonists, and
rituximab as second-line treatment. Among new-generation CD20-targeted therapy, only
veltuzumab has been tested for ITP. Preliminary study suggests that it could have similar
efficacy to rituximab. Options other than anti-CD20 treatment may modulate and/or inhibit the
B-cell compartment. Several monoclonal antibodies (MoAbs) directed against different
B-lymphocyte receptors or structures implicated in the cooperation between B and
T lymphocytes have been successfully tested in various autoimmune diseases. Testing these
options in ITP will be an exciting challenge.
Semin Hematol 50:S75–S82. C 2013 Published by Elsevier Inc.Open access under CC BY-NC-ND license.I
mmune thrombocytopenia (ITP) is a rare disease
characterized by low platelet count resulting in
autoimmune phenomena. For a long time the
disease was considered mainly related to autoanti-
bodies against platelet glycoproteins (GPs). There-
fore, the pathophysiologic aspects are complex and
probably reflect the heterogeneity of the disease.1
Impaired platelet production has been long sus-
pected and recently confirmed by a strong response
obtained with use of thrombopoietin receptor ago-
nists. In addition, in vitro studies suggested theblished by Elsevier Inc.
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Open access under CC BY-NC-ND license.involvement of CD8 T-cell destruction of platelets
as well as breakdown of tolerance perhaps because
of regulatory T-cell deficiency.2
B cells play an important role in the immune
response. Their major role is to produce antibodies.3
However, B cells are also efficient antigen-presenting
cells for T cells. This role appears important for
presenting low concentrations of antigens. The
process involves molecules such as B7/CD28 and
CD40/CD40 ligands on the surface of B cells and T
cells, respectively, which helps expand the number
of CD4þ T cells. B cells secrete cytokines such as
interleukin-1 (IL-1), IL-10, IL-6, interferon-g, and
tumor necrosis factor-a (TNF-a), which activate
macrophages, dendritic cells, and immunoregulatory
cells. These various functions explain why disor-
dered B-cell function can lead to the development of
autoimmune diseases, by the production of patho-
genic autoantibodies and a larger dysregulation of
the immune response. Finally, B cells play an
important role in normal body architecture and the
development of secondary lymphoid organs.
The role of B cells in the ITP pathology was first
reported more than 50 years ago with the Harrington–
Hollingsworth experiment demonstrating that plateletp S75–S82 S75
B. GodeauS76destruction was related to a plasma-derived factor.4
The factor was later identified to be antiplatelet anti-
bodies directed against GPs, mainly GPIIb/IIIa and
GPIb/IX. However, only about 50% of patients show
platelet antibodies. Failure to detect antibodies might
reflect poor test sensitivity but could be related to
mechanisms of platelet loss not involving B cells.
Thus, a rational approach to ITP treatment could
involve B-cell depletion such as with rituximab.RITUXIMAB FOR ITP
Human CD20
Human CD20 is a 33- to 37-kd non-glycosylated
phosphoprotein exclusively expressed in the B-cell
hematopoietic lineage.5 Its exact function and natu-
ral ligands are unknown. CD20 is closely associated
with the B-cell antigen receptor. It is not expressed
in hematopoietic stem cells or plasma cells, so
depleting a B-cell lineage with a monoclonal anti-
body (MoAb) directed against CD20 will not affect
the development of new B cells and is not associated
with a significant decrease in immunoglobulin (Ig)
production against pathogens. In theory, this sce-
nario limits the risk of infectious complications and
hypogammaglobulinemia.Development of Rituximab and Mode(s)
of Action
Rituximab is a human-to-mouse chimeric anti-CD20
MoAb initially developed 20 years ago to treat lym-
phoma. The mode of depletion of CD20þ cells is not
completely understood, but in vitro and animal
studies have demonstrated that antibody-dependent
cellular cytotoxycity (ADCC) is crucial.6 Complement-
dependent cytotoxicity (CDC) and apoptosis via a
direct effect of MoAb binding to CD20 may be also
involved. ADCC is mediated by effector cells express-
ing Fc-g receptors, such as natural killer cells and
macrophages. The degree of ADCC depends on the
effector target cell ratio, and polymorphism of the
Fc-g receptor on effector cells could determine the
efficacy of rituximab.
Rituximab was also developed for use with vari-
ous autoimmune diseases such as rheumatoid arthri-
tis (RA), systemic lupus erythematosus (SLE), and
autoimmune cytopenia.7–9 It induces continual,
rapid, profound and prolonged B-cell depletion.
However, the B-cell number returns to normal after
6–12 months, with repopulation of the B-cell pool
characterized by the appearance of immature B cells;
the number of CD27þ memory B cells remains
reduced for up to 2 years.10 The long-lived plasma
cell compartment does not appear to be affected by
rituximab, and IgG level remains stable in mostcases. However, antibody titers are reduced with
anti-pneumococcal vaccination.11
The mechanisms of action of rituximab in ITP are
not fully understood and are complex. Rituximab has
direct effects on antibody production but indirect
effects on cellular immunity.
The titers of platelet autoantibodies can decrease
markedly or even became undetectable after B-cell
depletion. Titers of platelet-associated antiplatelet
antibodies may differ between responders and non-
responders to treatment, and the timing of decreased
titers of platelet-associated antiplatelet antibodies
may be associated with increased platelet count.12
However, the autoantibody response is not constant
in responders, which suggests that other mecha-
nisms may be involved. Studies by Stasi and col-
leagues13,14 showed that the rituximab response is
related to changes in the T-cell compartment, in
particular a resolution of skewed distribution of
human T-cell receptors, changes in T-helper subsets
and improved regulatory T-cell function. In non-
responders, CD8 T-cell–mediated platelet or mega-
caryocyte destruction could be involved. In some
patients, both antibody and cellular elements may
contribute to thrombocytopenia.15
A study of the effect of rituximab on the spleen
implied the involvement of other mechanisms. The
spleen plays an important role in the pathophysio-
logic aspects of ITP. It is an important site of platelet
antibody production and of platelet destruction, as
shown by isotopic studies and the efficacy of
splenectomy with high response in ITP. Audia
et al16 showed that in some patients with no
response to rituximab who later underwent splenec-
tomy, rituximab had eliminated nearly all circulating
and splenic B cells but was not sufficient for a
clinical response. The authors showed plasma cells
persisting in the spleen. Moreover, patients with no
response to rituximab therapy show a marked
imbalance in ratio of T-helper cells type 1 to regu-
latory T cells. Mahe´vas et al17 analyzed the splenic B-
cell compartment in ITP patients without response
to rituximab. The authors confirmed that plasma
cells were the major residual splenic population and
a fraction were autoreactive, which accounted for
persistent disease and failure of rituximab treatment.
Using gene profiling and microarray assay, the
authors demonstrated a unique long-lived plasma
cell phenotype for some plasma cells.Efficacy of Rituximab in ITP
More than 10 years ago, Stasi et al18 reported the
results of the first open prospective study of 25
adults with chronic ITP who received 4 weekly
infusions of 375 mg/m2 rituximab. The authors
found an overall response rate of 52%. Six years
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of the literature, involving 313 patients. The overall
response rate was 62.5% and lasted from 2–48
months. Toxic effects were found; 2.9% of patients
died, but some of the deaths could have been due to
ITP rather than the treatment itself. From these
encouraging results, an open prospective study
was conducted to assess the efficacy and safety of
rituximab in 60 non-splenectomized adults who
were candidates for splenectomy.20 Two years after
rituximab therapy, 40% of patients showed sustained
platelet count of 30,000/L or more. The ability of
rituximab as an effective splenectomy-avoiding
option was recently confirmed in a meta-analysis of
randomized clinical trials and observational stud-
ies.21 The overall response rate was 57% for 368
non-splenectomized patients after rituximab ther-
apy. On univariate or multivariate mixed-effects
meta-regression, age was the most relevant associ-
ated factor, with better results in young patients.
The use of rituximab as first-line therapy in patients
with newly diagnosed ITP was investigated in a
prospective study comparing dexamethasone alone
and dexamethasone plus 4 weekly injections of
rituximab at a ‘‘standard dose’’ of 375 mg/m2.22
The addition of rituximab to dexamethasone signifi-
cantly improved the long-term efficacy rate, with a
sustained response of 85% at 6 months as compared
with 39% with dexamethasone alone. At a median
follow-up of 20 months, approximately 75% of the
initial responders showed a lasting response. Unlike
these good results, an anti-CD20 strategy appears not
to be indicated as standard first-line therapy in most
guidelines, and corticosteroids alone remain the gold
standard.23,24
Only few data on the long-term response of
rituximab are available because the duration of
follow-up has been limited in most reported studies.
A retrospective study of 72 adults with response of
at least 1 year and 65 children with response of any
duration showed an initial overall response rate of
57% in adults and children and 5-year estimates of
persistent response of 21% and 26%, respectively.25
Initial complete response and prolonged B-cell
depletion were significantly associated with sus-
tained response.The Optimal Therapeutic Schedule of
Rituximab for ITP
Dose(s)
Most studies used the ‘‘standard’’ dose used to
treat lymphoma (ie, 375 mg/m2); however, some
authors proposed a fixed dose of 4 weekly injections
of 100 mg.26–28 The most recent study with this dose
prospectively included 48 adults with symptomaticITP. The median time to response was 35 days
(range, 7–112 days) and was similar to that with
the standard regimen. The 12- and 24-month cumu-
lative relapse-free survival rates were 61% and 45%,
respectively. This study suggested that low-dose
rituximab is active but has moderate long-term
effect. A retrospective study recently conducted in
France included 107 patients with chronic ITP and
compared the standard dose and the ‘‘RA’’ regimen
of two fixed doses of 1000 mg on days 1 and 15.29
This schema was validated in RA in prospective
controlled study and is also used for other auto-
immune disease such as SLE or anti-neutrophil
cytoplasmic antibody-related necrotizing vasculi-
tis.7,30 For ITP, overall response rate and tolerance
were similar with both regimens, so this schema may
replace the standard regimen as a more convenient
schedule for the patient.Repeated Courses
Because relapse is frequently observed after the
initial response, Hasan et al31 tested the value of re-
treatment with rituximab with the same schedule as
the initial course or a doubling dose with and
without cyclophosphamide. Unfortunately, neither
combining rituximab with cyclophosphamide nor
doubling the rituximab dose increased the response
rate, and in 75% of patients, re-treatment induced
similar response. Because the safety of repeated
rituximab infusions is unknown, in our opinion, this
therapeutic strategy should be avoided and reserved
for select patients with disease refractory to other
therapies.Rituximab With Other Treatments
As indicated previously, a controlled randomized
study demonstrated that dexamethasone alone was
less effective than dexamethasone with rituximab
for ITP.22 Unfortunately, results of a randomized
study comparing rituximab alone and rituximab plus
dexamethasone have never been reported. However,
in a single-center pilot study, 36 adults received
4 weekly infusions of 375 mg/m2 and three 4-day
cycles of high-dose dexamethasone at 2-week inter-
vals32; the overall response rate was 86%. After a
median follow-up of 14 months, 74% of responding
patients showed a continual response. Five patients
showed continual complete responses from 24 to 50
months. From the history of patients previously
treated in the same unit with the standard regimen
(ie, 4 weekly injections of 375 mg/m2), rituximab
plus dexamethasone appeared to be active and
superior to rituximab alone. The response was better
for patients with a shorter duration of ITP (o1–2
years). Prospective studies should be conducted to
B. GodeauS78confirm these promising results and to better assess
the tolerance of this therapeutic schedule.
Safety of Rituximab in ITP
We need better knowledge of the safety of
rituximab in the short and long term. From the
literature, rituximab appears to be well tolerated,
but we lack studies of long-term tolerance. A large
prospective registry of patients receiving treatment
in daily practice for RA was established in France.33
The registry included 1,303 patients who were
monitored for a mean of 1.2  0.8 years. The rate
of severe infections was 5 per 100 patient-years and
appeared similar to that for patients with RA receiv-
ing other biotherapy. However, these reassuring data
cannot be extrapolated to ITP. Moreover, in real life,
the side effects of rituximab, particularly after a long
delay, are probably underreported. To answer this
important question, a prospective registry of ITP
patients receiving rituximab was established in
France 2 years ago.34 Only patients previously naive
for this treatment were included. Currently, 250
patients have been included. A follow-up of 5 years
is planned. This registry should allow for a better
picture of tolerance of rituximab in ITP.
Several risks of rituximab treatment are well
known and some can be easily prevented.35
Infusion-Related Reactions
Rare fatal reactions have been reported in patients
with RA, and physicians should not forget that
premedication with 100 mg methylprednisolone
should be systematically administered, according to
health authorities recommendations.
Infections and Virus Reactivation
This is a concern. This risk is difficult to quantify,
even if the data for patients receiving rituximab for
RA are reassuring (see above). Rituximab can be
associated with virus reactivation. This risk appears
to be high for patients with hepatitis B virus (HBV)
infection, and cases of fatal fulminant hepatitis have
been reported. Special care should be paid to screen-
ing for HBV. With the presence of markers of HBV,
other therapeutic options should be considered, even
if pre-emptive antiviral treatment could be an option.
An important question is the risk of fatal progressive
multifocal leukoencephalopathy caused by the John
Cunningham polyomavirus. This serious complica-
tion is, fortunately, exceptional and to our knowl-
edge, only two cases have been reported.36,37
Neutropenia
Late-onset neutropenia occurring usually several
months after the administration of rituximab hasbeen observed mainly in patients receiving the
treatment for chronic lymphocytic leukemia. This
risk for patients receiving rituximab for ITP is rare.
Neutropenia is usually transient and is not compli-
cated by severe infection. Its mechanism is not well
understood.38
Reduced Ig Levels
In theory, this risk should be rare because CD20 is
not expressed on mature B cells. However, we
occasionally observed patients with this complica-
tion a long time after rituximab administration.25
Ensuring that this complication is not the first
manifestation of common variable immunodefi-
ciency (CVID) syndrome is difficult because auto-
immune cytopenia is a frequent complication of
CVID.39 Even if the incidence of this complication
may be low, regular monitoring of IgG levels and for
a long time may be useful.
Suboptimal Vaccine Response
Some studies suggest impaired humoral immune
response to vaccines with rituximab treatment.11
Therefore, logically, vaccines should be administered
at least 2 to 4 weeks before the first rituximab
infusion in non-immunized patients. Anti-pneumo-
coccal, -haemophilus, and -meningococcus-C vacci-
nations appear crucial for non-splenectomized
patients. If a splenectomy is required in the year
after rituximab infusions, a suboptimal vaccine
response can be prolonged for 1 year.
Optimal Time to Administer Rituximab for ITP
The consensus is to administer corticosteroids or
intravenous Ig (IVIg) as first-line therapy in ITP.23,24
However, the effect of these treatments is frequently
only transient, and most patients show relapse. The
best second-line treatement is still debated and not
consensual. A panel of experts was unable to
formulate a clear strategy for the respective place
of splenectomy, thrombopoietin-receptor (TPO-r)
agonists and rituximab as second-line treatment.23
American Society Hematology (ASH) guidelines pro-
posed splenectomy (grade 1B) for patients with no
response to corticosteroids24; TPO-r agonists should
be reserved for patients with relapse after splenec-
tomy or those with contraindications to splenectomy
and for whom at least one other therapy failed
(grade 1B). Rituximab may be considered for
patients with no response to one line of therapy
such as corticosteroids, IVIg, or splenectomy (2C).
However, international consensus and ASH guide-
lines emphazise the general rule that treatment
should always be tailored to the individual patient
and that a recommendation should not replace the
best physician judgment and patient preference.
B-cell depletion in ITP S79According to these recommendations, some authors
recently proposed a personalized strategy including
several variables such as age of the patient, duration
of ITP, presence of comorbidities, results of isotopic
studies, patient choice, and possible restrictions on
the use of TPO-r agonists and/or rituximab by health
funding authorities.40 According to this schedule, a
candidate for rituximab as second-line treatment
could be a patient who refuses splenectomy but
who prefers treatment for cure, with high risk of
arterial or vein thrombosis, or with anticipated poor
compliance.
Rituximab as an Option for Patients With ITP Secondary to
Other DiseasesSecondary to Hepatitis C Virus (HCV) Infection. To
our knowledge, no case of HCV-infection–
associated ITP has been treated with rituximab.
Even if rituximab use is associated with a risk of
viral reactivation, this risk is probably low, and
rituximab has been used without problems in
other extra-hepatic manifestations related to HCV
infection such as mixed cryoglobulinemia or
necrotizing vasculitis.41
Secondary to HIV Infection. As with HCV infection,
data are lacking to adequately evaluate the use of
rituximab for these cases. However, rituximab
should be avoided in patients with HIV infection
and human herpes virus 8–related Kaposi sarcoma
because worse disease evolution has been
reported.
Secondary to SLE. Several uncontrolled studies of a
small number of patients suggested that rituximab
could be useful in this field. Previous data
suggested that rituximab could be associated with
risk of progressive multifocal leukoencephalopathy
in SLE. The French prospective registry reporting
the tolerance of rituximab in 136 SLE patients gave
reassuring data.42
Secondary to CVID Syndrome. The efficacy of
rituximab was retrospectively assessed in 22
patients with CVID syndrome-associated ITP.43
The overall response rate was 85%. Relapse was
observed in one third of patients after a mean
follow-up of 39 months. Re-treatment was
effective in most. Severe infections occurred in
one quarter of patients. Because of lack of a
control group, ensuring that these infections
were related to rituximab or to the CVID itself is
difficult. However, IVIg replacement appears
cautious, even in the absence of previous
infectious complications.NEW ANTI-CD20 ANTIBODY
Rituximab has greatly improved the outcome of
patients with B-cell malignancies. However, despite its
success, some patients show no response, which
points to new-generation CD20-targeted therapy.44
Second-generation MoAbs have been ‘‘humanized’’
or developed with a completely human IgG1 tail.
Third-generation anti-CD20 MoAbs have, in addition to
a humanized IgG, an ajusted Fc region modified to
outperform rituximab and to induce different effector
functions. Some third-generation anti-CD20 MoAbs are
potent CDC inducers. However, others do not induce
CDC but, rather, strongly promote cell death by
apoptosis. These new CD20-targeted MoAbs are
mainly developed for B-cell malignancies. Whether
they have better activity than rituximab for treating
autoimmune disease remains to be determined.
Among new-generation CD20-targeted therapy, only
veltuzumab has been tested for ITP.45 Veltuzumab is a
second-generation anti-CD20 MoAb. It is humanized
and delivered by subcutaneous injection. Compared to
rituximab, it has a slower off-rate. A multicenter, phase
I/II study evaluated various doses of veltuzumab in 2 to
4 weekly subcutaneous injections as monotherapy for
ITP patients. Most patients had been intensively
treated for chronic disease. Of the 40 patients with
evaluable data, the overall response rate was 68%. The
median time to relapse was correlated with the initial
response and was 14.2 months for patients with an
initial complete response. The response was 35% at
more than 1 year, and two patients showed response
at more than 3 years. Subcutaneous veltuzumab
appears to be promising. Further studies combining
veltuzumab with other agents such as dexamethasone
or as a maintenance regimen could be useful.OTHER OPTIONS TO INDUCE B-CELL
DEPLETION
Options other than anti-CD20 treatment may mod-
ulate and/or inhibit the B-cell compartment. Several
MoAbs directed against different B-lymphocyte recep-
tors or structures implicated in the cooperation
between B and T lymphocytes have been tested in
various autoimmune diseases, particularly RA and SLE.
Testing these molecules in ITP would be attractive.
Belimumab is a human monoclonal antibody that
inhibits B-cell activating factor (BAFF), also known as
B-lymphocyte stimulator (BLyS). BAFF enhances B-
cell survival; overexpression of BAFF results in
severe autoimmune disorders in mice, and patients
with various autoimmune diseases show elevated
levels of BAFF. Patients with ITP have shown this
increased BAFF phenotype, which suggests that new
therapeutic options such as belimumab targeting
BAFF may be developed for ITP.46
B. GodeauS80CD22 is a 140-kd member of the cell-surface
proteins that is expressed by most mature B-cell
lineages. As a co-receptor of the B-cell antigen
receptor, it contributes to sensitive control of the
B-cell response to antigens. Modulating CD22 activ-
ity has been suggested as a therapeutic approach to
such diseases. For example, epratuzumab is a novel
fully human CD22-targeting monoclonal antibody
that induces B-cell apoptosis. It is currently under
investigation as treatment for connective tissue dis-
orders, particularly SLE, with preliminary encourag-
ing results.8
T-cell activation depends on close contacts with
antigen-presenting cells. It requires several signals,
particularly an interaction between the B7 family
members B7-1 (CD80) and B7-2 (CD86) on the
surface of such cells and their ligand CD28,
expressed on T cells. CTLA-4 is a second receptor
for B7-1 and B7-2 that is expressed on the membrane
of activated T cells; it delivers a signal that inhibits T-
cell activation. CTLA4Ig (abatacept) is a soluble
version of CTLA-4. Like natural CTLA-4 molecules,
CTLA4Ig ligates B7-1 and B7-2 on antigen-presenting
cells and downregulates subsequent immune-
effector mechanisms. It has been successfully tested
in RA.47
BLys (BAFF), a proliferation-inducing ligand
(APRIL) is member of the TNF family that regulates
B-cell maturation, survival and function. BLys and
APRIL are overexpressed in various autoimmune
diseases and reportedly exist in vivo as homotrimers
and as BLyS/APRIL heterotrimers. In light of their
roles in B-cell function, BLys and APRIL may be
targets for novel treatments for autoimmune dis-
eases. Atacicept is a fully human recombinant fusion
protein that modulates B cells by neutralizing BLys
and APRIL activity and is in clinical development for
SLE and RA treatment.48,49
CD40-ligand (CD154) is expressed on activated
CD4-T lymphocytes and is essential for the T-cell–
dependent activation of B lymphocytes. Platelet-
associated CD154 expression is increased in ITP
and is able to drive the activation of autoreactive B
lymphocytes.50 Blockade of the CD40/CD154 signal
is a potential immunomodulatory strategy for ITP as
suggested by Kawana et al,51 who reported an
increase of platelet count in three patients treated
with a humanized monoclonal antibody directed
against CD154. No severe infections or thromboem-
bolic events occurred.50 However, this promising
result was not confirmed.CONCLUSIONS AND PERSPECTIVES
More than 10 years after the first reports of the
efficacy of rituximab for ITP, this treatment is now a
recognized option for ITP. Unlike TPO-r agonists,which are effective and well tolerated and have a
clear immediate overall response rate as compared
with rituximab, rituximab is able to reverse the
autoimmune process for disease cure. Identifying
patients who are more likely to show treatment
response is a major goal for the near future. Even if
rituximab appears to be well tolerated, better knowl-
edge of long-term safety is required. As well, we
must determine the best therapeutic schedule and
the potential interest of association with other
therapy such as dexamethasone. Testing the efficacy
and tolerance of other drugs modifying B-cell activity
will be also an exciting challenge.REFERENCES
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